NCT04377334

Mesenchymal Stem Cells (MSCs) in Inflammation-Resolution Programs of Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS)

Prospective Phase II Study: MSCs in Inflammation-Resolution Programs of SARS-CoV-2 Induced ARDS

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University Hospital Tuebingen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety, toxicity and immunological effects of infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells (MSCs) and whether this therapy has an influence on the resolution processes in ARDS patients infected with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Conditions

• ARDS
• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	MSC	infusion of allogeneic bone marrow-derived human mesenchymal stem (stromal) cells

Timeline

• Start date: 2022-05-01
• Primary completion: 2022-11-01
• Completion: 2023-02-01
• First posted: 2020-05-06
• Last updated: 2022-01-27

Locations

1 site across 1 country: Germany